LXT-101

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2006-2017
01220062017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
BACKGROUND The thermo-sensitive in situ gels based on copolymers are attractive as an injectable drug delivery carriers for… (More)
Is this relevant?
2015
2015
In this study, sustained-release of GnRH antagonist peptide LXT-101 was realized through oil formulation, and their releasing… (More)
Is this relevant?
2014
2014
OBJECTIVES To demonstrate the correlation between the nanostructure formation and the long duration of action in vivo of peptides… (More)
  • figure 1
  • figure 2
Is this relevant?
2013
2013
LXT-101, a cationic peptide is a novel antagonist of gonadotropin-releasing hormone (GnRH) for prostate cancer treatment. However… (More)
  • figure 2
  • figure 4
  • figure 6
Is this relevant?
2011
2011
OBJECTIVES Multivesicular liposomes (MVLs) are often used as an appropriate carrier for delivering peptides due to high drug… (More)
Is this relevant?
2009
2009
Using a simple method to determine the interaction between peptide and lipid bilayer and then deciding how to modify formulation… (More)
Is this relevant?
2008
2008
This paper developed a sensitive and specific liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/MS) method… (More)
Is this relevant?
2006
2006
LXT-101 is a newly developed GnRH (gonadotropin-releasing hormone) analogue. In this study, the in vivo pharmacological profile… (More)
Is this relevant?
2006
2006
A sustained release poly(DL-lactide-co-glycolide) (PLGA) microsphere delivery system to treat prostate cancer for a luteinizing… (More)
Is this relevant?